UROCORTIN, A MAMMALIAN NEUROPEPTIDE RELATED TO FISH UROTENSIN-I AND TO CORTICOTROPIN-RELEASING FACTOR

被引:1328
作者
VAUGHAN, J
DONALDSON, C
BITTENCOURT, J
PERRIN, MH
LEWIS, K
SUTTON, S
CHAN, R
TURNBULL, AV
LOVEJOY, D
RIVIER, C
RIVIER, J
SAWCHENKO, PE
VALE, W
机构
[1] SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037
[2] SALK INST BIOL STUDIES,NEURONAL STRUCT & FUNCT LAB,LA JOLLA,CA 92037
关键词
D O I
10.1038/378287a0
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Corticotropin-releasing factor (CRF), a peptide first isolated from mammalian brain(1), is critical in the regulation of the pituitary-adrenal axis, and in complementary stress-related endocrine, autonomic and behavioural responses(2). Fish urotensin I and amphibian sauvagine were considered to be homologues(3) of CRF until peptides even more closely related to CRF were identified in these same vertebrate classes(4,5). We have characterized another mammalian member of the CRF family and have localized its urotensin-like immunoreactivity to, and cloned related complementary DNAs from, a discrete rat midbrain region. The deduced protein encodes a peptide that we name urocortin, which is related to urotensin (63% sequence identity) and CRF (45% sequence identity). Synthetic urocortin evokes secretion of adrenocorticotropic hormone (ACTH) both in vitro and in vivo and binds and activates transfected type-1 CRF receptors(6,9), the subtype expressed by pituitary corticotropes. The coincidence of urotensin-like immunoreactivity with type-2 CRF receptors(10-13) in brain, and our observation that urocortin is more potent than CRF at binding and activating type-2 CRF receptors, as well as at inducing c-Fos (an index of cellular activation) in regions enriched in type-2 CRF receptors, indicate that this new peptide could be an endogenous ligand for type-2 CRF receptors.
引用
收藏
页码:287 / 292
页数:6
相关论文
共 30 条
  • [21] Loewy A.D., Central Regulation of Autonomic Functions, pp. 268-285, (1990)
  • [22] Loewy A.D., Saper C.B., Yamodis N.D., Brain Res, 141, pp. 153-159, (1978)
  • [23] Webster W.R., The Rat Nervous System, pp. 797-831, (1995)
  • [24] Saper C.B., Swanson L.W., Cowan W.M., J. comp. Neuro, 183, pp. 689-706, (1979)
  • [25] Morgan J.I., Curran T., A. Rev. Neurosci, 14, pp. 421-451, (1991)
  • [26] Lederis K., Et al., Rec. Prog. Horm. Res, 41, pp. 553-576, (1985)
  • [27] Vale W., Et al., Meth. Enzym, 103, pp. 565-577, (1983)
  • [28] Sutton S.W., Et al., Endocrinology, 136, pp. 1097-1102, (1995)
  • [29] Chung R.Y., Mason P., Strassman A., Maciewicz R., Neurosci. Lett, 83, pp. 13-19, (1987)
  • [30] Chan R.K.W., Brown E.R., Ericsson A., Kovacs K.J., Sawchenko P.E., J. Neurosci, 13, pp. 5125-5138, (1993)